Identification of early diagnosis markers of pancreatic ductal adenocarcinoma (PDAC) using publicly available transcriptomic tumor and blood sample data

Author:

Sionakidis Aristeidis1,Lalagkas Panagiotis Nikolaos2,Malousi Andigoni3,Vizirianakis Ioannis S.3

Affiliation:

1. University of Edinburgh

2. University of Massachusetts

3. Aristotle University of Thessaloniki

Abstract

Abstract Pancreatic ductal adenocarcinoma (PDAC) is the most frequently diagnosed form of pancreatic cancer worldwide. PDAC is associated with poor survival rate mainly due to the disease being usually diagnosed at late stages. Publicly available gene expression data from 10 studies with tumour tissue (448 samples) and/or blood samples (128 samples) from PDAC patients were pooled together and analysed for the identification of stage-specific (American Joint Committee for Cancer, AJCC staging) and global diagnostic markers. Validation of markers was performed using Cancer Genome Atlas (TCGA) PDAC expression data. Differential gene expression analysis was carried out to compare tumour and normal samples (stage-specific tissue samples vs. normal tissue samples and stage-agnostic blood samples vs. normal blood samples). Active subnetwork search and miRNA enrichment analysis were used to identify enriched gene networks and miRNA interactions. We identified 820 consistently deregulated genes in tissue samples of all stages and blood samples. Active subnetwork analysis revealed enriched ribosome, proteasome, adherens junction and cell cycle pathways across all stages and blood samples suggesting biological plausibility. Stage-specific enriched miRNAs with diagnostic potential were also identified (miR-21, miR-29, miR-124, miR-30, for stages 1-4 respectively). Extensive gene expression deregulation was found in all tumor stages with significant overlap. Additionally, miRNA contribution to PDAC pathology may be important and probably mediated by distinct miRNAs in each stage of PDAC. We therefore present a list of markers and miRNAs that could potentially act as a diagnostic tool for early detection of PDAC onset.

Publisher

Research Square Platform LLC

Reference48 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA Cancer J Clin,2021

2. Cancer statistics, 2020;Siegel RL;CA Cancer J Clin,2020

3. Genetics and biology of pancreatic ductal adenocarcinoma;Ying H;Genes Dev,2016

4. Vizirianakis IS, Miliotou AM, Mystridis GA, Andriotis EG, Andreadis II, Papadopoulou LC, et al. Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics. https://doi.org/10.1080/23808993.2019.1605828. 2019;4:139 – 51, publisher = Taylor \& Francis.

5. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy;Collisson EA;Nat Med,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3